Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
about
Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Anti-myeloma effects of ruxoli ...... nhibition in myeloma patients.
@en
Anti-myeloma effects of ruxoli ...... nhibition in myeloma patients.
@nl
type
label
Anti-myeloma effects of ruxoli ...... nhibition in myeloma patients.
@en
Anti-myeloma effects of ruxoli ...... nhibition in myeloma patients.
@nl
prefLabel
Anti-myeloma effects of ruxoli ...... nhibition in myeloma patients.
@en
Anti-myeloma effects of ruxoli ...... nhibition in myeloma patients.
@nl
P2093
P1433
P1476
Anti-myeloma effects of ruxoli ...... nhibition in myeloma patients.
@en
P2093
Angela I P Eugenio
Luiz Felipe G Sanson
Mariana B de Oliveira
Mariana F de Carvalho
Rodrigo C Fernando
Veruska L Fook-Alves
Walter M T Braga
P304
P356
10.1016/J.CANLET.2017.06.016
P407
P577
2017-06-20T00:00:00Z